Bydureon | FDA holds off on approving extended-release Byetta
The FDA has requested more studies on Bydureon before it approves the extended-release diabetes drug. This leaves Eli Lilly in a tough spot.
Wednesday, October 20th, 2010 by By Mary Rice
Recent Conversations